ABSTRACT
Objective] To investigate plasma level of omentin in chronic hemodialysis patients and its correlation with BMI,serum creatinine,fasting glucose,blood lipid and Homa-IR. [Methods] The study included 80 health people as control group and 62 chronic hemodialysis patients .A double antibody sandwich enzyme-linked immuno sorbent assay ( ELISA ) method was applied to detect the level of serum omentin and homeostasis model assessment of insulin resistant ( Homa-IR) to assess the insulin resistance index ,analysis being done on correlation between serum omentin and other indexes . [ Results ] The levels of plasma omentin was significantly higher in hemodialysis patients than those in control group ( P<0.01).ESRD(end-stage renal disease) patients with diabetes had lower level of plasma omentin than those without diabetes .The serum level of omentin had negative correlation with BMI and Homa-IR, and positive correlation with HDL-C, serum creatinine . [ Conclusion] The serum level of omentin proves to be ele-vated in ESRD patients receiving hemodialysis;and those with diabetes had lower levels of plasma omentin than those without .
ABSTRACT
Thirteen of 4-anilinoquinazoline derivatives with imine groups at position 6 of quinazoline ring were synthesized and their antitumor activities were evaluated by MTT assay and Western blotting analysis. Among these compounds, 13a-131 were reported first time. The MTT assay was carried out on three human cancer cell lines (A549, HepG2 and SMMC7721) with EGFR highly expressed. Among the tested compounds, 13i and 13j exhibited notable inhibition potency and their IC50 values on three cell lines were equivalent to or less than those of gefitinib. Compound 14, without imine group substituted, displayed excellent inhibitor potency only on A549 cell line. Compounds 14 and 13j were chosen to perform Western blotting analysis on A549. The results showed that both of the compounds could inhibit the expression level of phosphorylated EGFR remarkably. It was concluded that the inhibitor potency of compound 14 was almost equivalent to that of gefitinib and the inhibitor potency of 13j was better than that of gefitinib.
Subject(s)
Humans , Aniline Compounds , Pharmacology , Antineoplastic Agents , Pharmacology , Cell Line, Tumor , Inhibitory Concentration 50 , Phosphorylation , Quinazolines , Pharmacology , ErbB ReceptorsABSTRACT
<p><b>OBJECTIVE</b>To investigate the long term survival of MDR-TB patients compared to non-MDR-TB in Henan province in 2010.</p><p><b>METHODS</b>Participants were randomly selected in 2010 from a dataset generated by an anti-TB drug resistance surveillance survey conducted by the Tuberculosis Control Institute, Henan Centre for Disease Control and Prevention in 2001, supported by the World Health Organization. Information on patient's demographic profile and medical records was extracted by trained doctors and nurses at local anti-TB dispensaries. Interviews were carried out using questionnaires to collect information on the socioeconomic features and survival status. Bivariate and multivariate with logistic regression were performed for data analysis.</p><p><b>RESULTS</b>The long term outcome of MDR-TB patients was much poorer when compared to non-MDR-TB patients. The case fatality was much higher among MDR-TB than non-MDR-TB patients (22.1% vs. 6.7%). The risk factors associated with the poorer outcome would include drug resistance status, disease relapse, hospitalization for treatment and long treatment period. Compared to non-MDR-TB, the survival time for MDR-TB was much shorter after having had the disease (6.7 years vs. 8.0 years).</p><p><b>CONCLUSION</b>MDR-TB patients had poor long term outcomes. As most of the cured TB patients were under productive age in the society, the high case fatality rate of MDR-TB would impose big burden on the related family and communities. Findings from this study suggested that the TB control programs should involve more efforts be paid on MDR-TB control, in order to reduce the burden of the disease.</p>